^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Published date:
05/01/2019
Excerpt:
Overall, a decrease in DUSP6 was observed on treatment; 2 of 3 patients with a decrease >50% achieved a PR on treatment Table 4; Supplementary Table S9).
DOI:
10.1158/1078-0432.CCR-18-1959